Kazia Therapeutics Ltd
KZIA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001075880
No open-market purchases or sales by Kazia Therapeutics Ltd insiders were filed in the last 90 days; 35 institutions reported holding it in 13F filings for Q2 2026, worth $50.7M in total; no superinvestor holds it.
13F holders, Q4 2024
Institutional positions in Kazia Therapeutics Ltd as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 11
- −7 vs. Q3 2024
- Shares held
- 321.7K
- +107.1K (+49.9%) vs. Q3 2024Converted for a 1-for-10 split
- Total value
- $569.1K
- −$352.9K (−38.3%) vs. Q3 2024
- New holders
- 2
- 5 more added
- Sold out
- 9
- 2 more reduced
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting KZIA on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 35 | $50.7M |
| Q1 2026 | 23 | $13.0M |
| Q4 2025 | 22 | $17.1M |
| Q3 2025 | 11 | $1.14M |
| Q2 2025 | 10 | $902.9K |
| Q1 2025 | 10 | $120.9K |
| Q4 2024 | 11 | $569.1K |
| Q3 2024 | 18 | $922.0K |
| Q2 2024 | 11 | $89.5K |
| Q1 2024 | 11 | $115.5K |
| Q4 2023 | 18 | $2.15M |
| Q3 2023 | 10 | $235.9K |
| Q2 2023 | 9 | $327.6K |
| Q1 2023 | 8 | $279.4K |
| Q4 2022 | 10 | $262.0K |
| Q3 2022 | 9 | $527.0K |
| Q2 2022 | 12 | $1.24M |
| Q1 2022 | 12 | $2.90M |
| Q4 2021 | 12 | $4.01M |
| Q3 2021 | 18 | $5.03M |
| Q2 2021 | 15 | $4.35M |
| Q1 2021 | 14 | $4.60M |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Kazia Therapeutics Ltd; share changes are against Q3 2024.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| MAI Capital Management | 139,208 | $246.4K | 0.00% | +2,819+2.1% | AddedConverted for a 1-for-10 split |
| Barclays PLC | 120,000 | $212.4K | 0.00% | +120,000 | New |
| UBS Group AG | 27,547 | $48.8K | 0.00% | +2,602+10.4% | AddedConverted for a 1-for-10 split |
| Morgan Stanley | 23,442 | $41.5K | 0.00% | +1,416+6.4% | AddedConverted for a 1-for-10 split |
| JPMorgan Chase & Co | 7,204 | $12.8K | 0.00% | +3,421+90.5% | AddedConverted for a 1-for-10 split |
| Rhumbline Advisers | 2,778 | $4.91K | 0.00% | 00.0% | UnchangedConverted for a 1-for-10 split |
| Citigroup Inc | 720 | $1.27K | 0.00% | +720 | New |
| Simplex Trading, LLC | 710 | $1.00K | 0.00% | +660+1,305.9% | AddedConverted for a 1-for-10 split |
| Advisor Group Holdings, Inc. | 50 | $88 | 0.00% | 00.0% | UnchangedConverted for a 1-for-10 split |
| Allworth Financial LP | 8 | $11 | 0.00% | −1−8.0% | ReducedConverted for a 1-for-10 split |
| Wells Fargo & Company | 2 | $4 | 0.00% | −48−96.0% | ReducedConverted for a 1-for-10 split |
| Citadel Advisors LLC | 0 | $0 | 0.00% | −6,048−100.0% | Sold outConverted for a 1-for-10 split |
| Jane Street Group, LLC | 0 | $0 | 0.00% | −4,611−100.0% | Sold outConverted for a 1-for-10 split |
| United Bank | 0 | $0 | 0.00% | −4,400−100.0% | Sold outConverted for a 1-for-10 split |
| Commonwealth Equity Services, LLC | 0 | $0 | 0.00% | −3,050−100.0% | Sold outConverted for a 1-for-10 split |
| XTX Topco Ltd | 0 | $0 | 0.00% | −2,340−100.0% | Sold outConverted for a 1-for-10 split |
| Captrust Financial Advisors | 0 | $0 | 0.00% | −1,527−100.0% | Sold outConverted for a 1-for-10 split |
| Geode Capital Management, LLC | 0 | $0 | 0.00% | −1,478−100.0% | Sold outConverted for a 1-for-10 split |
| Traynor Capital Management, Inc. | 0 | $0 | 0.00% | −1,000−100.0% | Sold outConverted for a 1-for-10 split |
| AdvisorNet Financial, Inc | 0 | $0 | 0.00% | −1−100.0% | Sold outConverted for a 1-for-10 split |